These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10500572)

  • 1. Risk factors that influence the incidence and severity of MMF adverse events in renal transplant patients: relationship with corticosteroid dosage, renal function, sex, and patient age.
    Puig JM; Fernández-Crespo P; Lloveras J; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2270-1. PubMed ID: 10500572
    [No Abstract]   [Full Text] [Related]  

  • 2. Beneficial effects of low-toxicity regimens with MMF in renal recipients with late allograft dysfunction.
    Folkmane I; Bernarde K; Bicans J; Amerika D; Rozentals R
    Transplant Proc; 2003 Mar; 35(2):789-90. PubMed ID: 12644138
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
    Nakache R; Weinbroum A; Merhav H; Katz P; Kaplan E
    Transplant Proc; 2001 May; 33(3):2294-5. PubMed ID: 11377533
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolerance of mycophenolate mofetil is dependent on kidney function.
    Puggia R; Rizzolo M; Maresca MC; Calconi G; Vianello A
    Transplant Proc; 1998 Aug; 30(5):2228. PubMed ID: 9723450
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
    Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
    Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
    [No Abstract]   [Full Text] [Related]  

  • 7. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glucocorticoid-free immunosuppressive protocol on serum lipids in renal transplant patients.
    Nowacka-Cieciura E; Soluch L; Cieciura T; Lewandowska D; Durlik M; Shaibani B; Serafinowicz A; Szmidt J; Rowiński W; Lao M
    Transplant Proc; 2000 Sep; 32(6):1339-43. PubMed ID: 10995973
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
    Houde I; Isenring P; Boucher D; Noël R; Lachanche JG
    Transplantation; 2000 Oct; 70(8):1251-3. PubMed ID: 11063351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction.
    Islam MS; Francos GC; Dunn SR; Burke JF
    Transplant Proc; 1998 Aug; 30(5):2230-1. PubMed ID: 9723452
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols.
    Meier-Kriesche HU; Friedman G; Jacobs M; Mulgaonkar S; Vaghela M; Kaplan B
    Transplantation; 1999 Nov; 68(10):1496-502. PubMed ID: 10589946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from cyclosporine to sirolimus in stable renal transplant recipients.
    Sennesael JJ; Bosmans JL; Bogers JP; Verbeelen D; Verpooten GA
    Transplantation; 2005 Dec; 80(11):1578-85. PubMed ID: 16371929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMF-based regimen in maintenance therapy after kidney transplantation.
    Wu MJ; Shu KH; Cheng CH; Chen CH; Lian JD
    Transplant Proc; 2000 Nov; 32(7):1748-50. PubMed ID: 11119918
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Spanish Group of the CellCept Study.
    Puig i Marí JM
    Transplant Proc; 1999 Sep; 31(6):2256-8. PubMed ID: 10500566
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.